Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (764)	5/10/1999 5:18:00 PM
From: arnie h	Read Replies (3) \| Respond to of 1386

Dr. John: It is certainly a positive that sales of Alrex and Lotemax are growing but they are obviously growing at a rate well below what the company had expected and what is needed to move the stock price. If revenues had come anyplace near what the company had expected, I doubt the stock price would be about a 4 year low. At this point, the cash on hand doesn't seem enough to go very far without another infusion unless a money infusing deal is made fairly soon for HU 211. This seems unlikely in the face of the current and persistent amount of short selling. Fortunately, they did structure a reasonable financial arrangement so no serious disruption seems around the bend. On the bright side, the company is adding value through it's increasing tax loss. Perhaps, the conference call will be more encouraging than the numbers. I certainly hope so. Arnie